Stocktoria
ELI LILLY & Co LLY
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1970-07-09
ELI LILLY & Co financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B |
| R&D expense | — | — | — | $7.2B | $6.9B |
| SG&A expense | $11.1B | $8.6B | $7.4B | $6.4B | $6.4B |
| Interest expense | — | — | $485.9M | $331.6M | $339.8M |
| Income tax | $5.1B | $2.1B | $1.3B | $561.6M | $573.8M |
| Net income | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Operating cash flow | $16.8B | $8.8B | $4.2B | $7.6B | $7.4B |
| Cash & equivalents | $7.3B | $3.3B | $2.8B | $2.1B | $3.8B |
| Inventory | $13.7B | $7.6B | $5.8B | $4.3B | $3.9B |
| Total assets | $112.5B | $78.7B | $64.0B | $49.5B | $48.8B |
| Shareholders' equity | $26.5B | $14.3B | $10.9B | $10.8B | $9.2B |
Source: SEC EDGAR filings · CIK 0000059478 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.